Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05137054 · ClinicalTrials.gov registry record · Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
A Phase 1 study of Multiple Myeloma, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 317
- Enrollment target
- 20
- Study locations
NCT05137054 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 317 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05137054, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 317 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma * What side effects may happen from taking linvoseltamab together with another cancer treatment * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Carfilzomib
- DRUG Linvoseltamab
- DRUG Bortezomib
Study Locations (20)
Other
- Centre Hospitalier Universitaire Angers - Angers
- CHU Montpellier - Departement D'Hematologie - Montpellier
- Saint Antoine Hospital - Paris
- Institut Gustave Roussy - Villejuif
New York
- Weill Cornell Medicine/New York Presbyterian Hospital - New York
- New York Presbyterian Hospital Columbia University Medical Center - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Wake Forest University Health Sciences - Winston-Salem
California
- Scripps Clinic Torrey Pines - La Jolla
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Indiana
- Indiana University Health Simon Cancer Center - Indianapolis
Massachusetts
- Dana Farber/Harvard Cancer Center - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2022-08-17 |
| Est. Completion | 2034-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05137054
The ClinicalTrials.gov registry entry for NCT05137054 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (42% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Lenalidomide is the first listed.
NCT05137054 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05137054 about?
NCT05137054 is a clinical study titled "A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments". This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that re...
What is the current status of trial NCT05137054?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 317 participants. The study started on 2022-08-17. Estimated completion is 2034-09-26.
What conditions does trial NCT05137054 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05137054?
The interventions under investigation include: Lenalidomide (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), Linvoseltamab (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT05137054?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05137054 being conducted?
This trial has 20 study locations across California, Georgia, Indiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.